SCHEMBL7308485

SCHEMBL7308485

N#Cc1ccc(COc2ccc3c(c2)c(CCN)cn3Cc2ccc(C(=O)O)o2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.47
IGF1R P08069 6/20 0.47
FLT4 P35916 6/20 0.47
KDR P35968 6/20 0.47
PPARD Q03181 3/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
LTB4R Q15722 2/20 0.42
LTB4R2 Q9NPC1 2/20 0.42
PTGER4 P35408 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
ALKBH1 Q13686 1/20 0.40
POLB P06746 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7319193 0.92 FFAR1 (0.47) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7318362 0.90 EGFR (0.54) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7319697 0.88 EGFR (0.48) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7319701 0.88 EGFR (0.61) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7314343 0.85 LTB4R (0.51) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7317740 0.83 EGFR (0.51) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7306051 0.83 PPARG (0.54) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7317916 0.83 EGFR (0.47) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7310884 0.83 EGFR (0.55) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7318750 0.82 EGFR (0.54) EGFRIGF1RFLT4KDRPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US claimed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO claimed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 EGFR 4683/4885IGF1R 4834/4885FLT4 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.